Priya Singhal Sells 748 Shares of Biogen (NASDAQ:BIIB) Stock

Biogen Inc. (NASDAQ:BIIB) insider Priya Singhal sold 748 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider directly owned 6,271 shares of the company’s stock, valued at approximately $1,124,390.30. The trade was a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Biogen Stock Performance

Shares of BIIB stock opened at $185.45 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04. The firm has a 50-day moving average of $176.48 and a 200-day moving average of $155.92. Biogen Inc. has a one year low of $110.04 and a one year high of $190.20. The company has a market cap of $27.21 billion, a P/E ratio of 16.91, a P/E/G ratio of 1.48 and a beta of 0.16.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BIIB shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Hsbc Global Res downgraded shares of Biogen from a “hold” rating to a “moderate sell” rating in a report on Wednesday, December 10th. Tudor Pickering set a $157.00 target price on shares of Biogen in a research note on Monday, November 3rd. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Finally, Robert W. Baird lowered their price target on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Eleven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $192.58.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Nature Medicine published pivotal DEVOTE results showing the high‑dose nusinersen regimen produced statistically significant motor and biomarker improvements versus lower dose / untreated comparators; safety was broadly consistent and the regimen is under FDA review with an April 3 PDUFA date — a clear potential revenue and label expansion catalyst for SPINRAZA. Nature Medicine Publishes DEVOTE Results
• Positive Sentiment: RBC Capital issued a buy/outperform view on BIIB, which supports upward price momentum by increasing institutional confidence and may attract more buyers ahead of earnings and the PDUFA decision. Biogen Receives a Buy from RBC Capital
• Neutral Sentiment: Market previews flag Q4 results and guidance as near‑term drivers — MS franchise pressures are a headwind but growth from newer assets (Leqembi, Skyclarys) could help offset declines; earnings delivery will likely drive short‑term volatility. Biogen Reports Q4: Everything You Need To Know Ahead Of Earnings
• Neutral Sentiment: Zacks preview notes new drug dynamics are key heading into Q4 — useful context but not an immediate directional trigger absent surprises in the print or guidance. New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
• Neutral Sentiment: Bernstein maintained a Hold (market‑perform) with a ~$191 target, signaling mixed near‑term fundamentals but acknowledging optional upside from emerging assets — this keeps analyst sentiment balanced. Biogen: Unexciting Near-Term Fundamentals but Optionality in Emerging Assets
• Negative Sentiment: An insider (Priya Singhal) disclosed a sale of 748 shares (~$134k) on Feb 2; small in size but sometimes viewed as a modest negative signal by some investors. Insider Form 4 — Priya Singhal Sale

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC boosted its stake in shares of Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 68 shares during the last quarter. CVA Family Office LLC raised its position in shares of Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 71 shares during the last quarter. Davis Investment Partners LLC lifted its stake in shares of Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 71 shares during the period. Optas LLC boosted its position in Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 73 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its position in Biogen by 22.5% during the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 76 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.